Skip to contentO
Oramed Pharmaceuticals Inc.
O
ORMPOramed Pharmaceuticals Inc. Q3 2017 · 10-Q
Revenue$617.00K$617.00KN/M vs Q3 2016 Net Income-$1.97M-$1.97MN/M vs Q3 2016 EPS Diluted$0.15$0.15±0.0% vs Q3 2016 Operating Income-$2,155,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Oramed Pharmaceuticals Inc. · CIK 1176309 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$2,359,000N/M Margins · derivedOperating margin-349.3%+945.2 pt vs Q3 2016
Net margin-318.5%+906.1 pt vs Q3 2016
ended May 31, 2017 · filed Jul 6, 2017 · 36 d after period end